Takeda Pharmaceutical Co. Ltd. Buys Shares of 203,190 Rani Therapeutics Holdings, Inc. (NASDAQ:RANI)

Takeda Pharmaceutical Co. Ltd. acquired a new stake in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 203,190 shares of the company’s stock, valued at approximately $278,000. Rani Therapeutics makes up 1.0% of Takeda Pharmaceutical Co. Ltd.’s portfolio, making the stock its 10th biggest position. Takeda Pharmaceutical Co. Ltd. owned about 0.35% of Rani Therapeutics at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Stifel Financial Corp lifted its holdings in Rani Therapeutics by 100.4% in the 3rd quarter. Stifel Financial Corp now owns 269,768 shares of the company’s stock valued at $583,000 after purchasing an additional 135,148 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Rani Therapeutics by 14.3% in the third quarter. Geode Capital Management LLC now owns 172,261 shares of the company’s stock valued at $372,000 after buying an additional 21,527 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Rani Therapeutics during the fourth quarter valued at approximately $62,000. Finally, Janney Montgomery Scott LLC acquired a new stake in Rani Therapeutics during the fourth quarter worth approximately $37,000. Institutional investors and hedge funds own 30.19% of the company’s stock.

Rani Therapeutics Stock Down 0.7 %

Shares of NASDAQ RANI opened at $1.43 on Thursday. The stock has a market capitalization of $81.92 million, a PE ratio of -1.35 and a beta of 0.14. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 2.34. The firm has a fifty day moving average of $1.51 and a 200-day moving average of $1.86. Rani Therapeutics Holdings, Inc. has a 52-week low of $1.24 and a 52-week high of $8.75.

Wall Street Analyst Weigh In

Several research analysts have weighed in on RANI shares. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Rani Therapeutics in a report on Friday, February 7th. Canaccord Genuity Group reiterated a “buy” rating and issued a $9.00 target price on shares of Rani Therapeutics in a research note on Wednesday, February 26th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Rani Therapeutics presently has an average rating of “Buy” and an average target price of $12.33.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.